POSC POSITRON CORP
Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 844985 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-572.6%
Operating margin-2,287.6%
Net margin-2,307.6%
FCF margin—
EBITDA margin-2,278.9%
Returns
ROE-2,479.9%
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets115.0%
Debt / equity—
Current ratio0.71x
Interest coverage-75.37x
Cash quality & payout
Operating cash flow / net income0.37x
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20142014-12-31 | FY20132013-12-31 | FY20122012-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $461,452 | $587,500 | $1.47M | $1.63M | $2.80M |
| Cost of revenue | $2.58M | $929,484 | $1.36M | $1.21M | $1.97M |
| Gross profit | -$2.11M | -$341,984 | $104,000 | $424,000 | $829,000 |
| R&D expense | — | — | $471,000 | $564,000 | $940,000 |
| SG&A expense | $8.38M | $1.86M | $2.19M | $2.78M | $4.33M |
| Operating income | -$10.50M | -$2.21M | -$2.74M | -$3.34M | -$4.72M |
| Interest expense | $125,338 | $142,402 | $1.82M | $2.14M | $1.75M |
| Pretax income | — | — | -$2.58M | -$7.10M | -$7.96M |
| Income tax | — | — | $0 | $0 | $0 |
| Net income | -$10.60M | -$2.38M | -$2.58M | -$7.10M | -$7.96M |
| EBITDA | -$10.47M | -$2.18M | -$2.59M | -$3.18M | -$4.50M |
| EPS (basic) | -0.34 | -0.09 | 0.00 | 0.00 | -0.01 |
| EPS (diluted) | -0.34 | -0.09 | 0.00 | 0.00 | -0.01 |
| Weighted avg. shares (diluted) | 30.89M | 25.98M | 3.70B | 1.45B | 1.27B |
| Banking | |||||
| Deposits | $375,000 | $375,000 | $10,000 | $18,000 | $53,000 |
| Balance sheet | |||||
| Cash & equivalents | $2.52M | $69,791 | $208,000 | $1.74M | $243,000 |
| Receivables | $8,333 | $16,667 | $175,000 | $247,000 | $273,000 |
| Inventory | $680,000 | $1.26M | $330,000 | $547,000 | $551,000 |
| Current assets | $3.34M | $1.35M | $730,000 | $2.57M | $1.10M |
| PP&E, net | $105,752 | $34,103 | $919,000 | $1.04M | $1.17M |
| Goodwill | — | — | $0 | $0 | $346,000 |
| Intangibles | — | — | $9,000 | $10,000 | $358,000 |
| Total assets | $4.00M | $1.80M | $1.87M | $3.88M | $2.69M |
| Current liabilities | $2.40M | $2.43M | $2.70M | $14.66M | $8.11M |
| Short-term debt | — | — | $1.06M | — | — |
| Long-term debt | $153,686 | $24,302 | $1.07M | — | $689,000 |
| Total debt | $153,686 | $24,302 | $2.13M | — | $689,000 |
| Total liabilities | $2.56M | $2.46M | $2.71M | $15.12M | $8.88M |
| Shareholders' equity | $1.44M | -$656,725 | -$837,000 | -$11.24M | -$6.19M |
| Net debt | -$2.37M | -$45,489 | $1.92M | — | $446,000 |
| Shares outstanding | 32.80M | 27.31M | 13.89M | 1.45B | 1.45B |
| Cash flow statement | |||||
| Operating cash flow | -$4.70M | -$1.73M | -$2.42M | -$3.05M | -$2.24M |
| Capital expenditure | — | — | $26,000 | $16,000 | $73,000 |
| Free cash flow | — | — | -$2.44M | -$3.06M | -$2.31M |
| Investing cash flow | -$99,026 | — | -$26,000 | -$16,000 | -$72,000 |
| Financing cash flow | $7.25M | $1.70M | $905,000 | $4.56M | $2.55M |
| Depreciation & amortization | $27,377 | $22,055 | $152,000 | $160,000 | $226,000 |
| Stock-based compensation | $4.98M | — | $89,000 | $656,000 | $1.78M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.